GlycoMimetics, Inc. (GLYC) announced that the FDA has granted a Rare Pediatric Disease designation for its lead candidate rivipansel for the treatment of sickle cell disease (“SCD”) in patients 18 years old and younger. Sickle cell disease is a group of blood disorders typically inherited from a person's parents.
Shares of the company have decreased 38.2% year to date compared with the industry’s 7.6% decline.
Rivipansel is a glycomimetic drug candidate and the company plans to release full data set from the phase III RESET program at upcoming medical meetings.
The Rare Pediatric Disease designation makes the candidate eligible for a Rare Pediatric Disease Priority Review Voucher (“PRV”) upon approval. A PRV allows the holder of the voucher to receive an expedited six-month review from the FDA for new drug application or biologics license application instead of the usual ten-month review. Priority review vouchers are also awarded by the FDA for the development of treatments for certain tropical diseases and medical countermeasures.
There are some companies that are developing or have developed candidates for the treatment of SCD. bluebird (BLUE - Free Report) is developing lentiGlobin gene therapy for adult and adolescent patients with SCD. Global Blood Therapeutics’ Oxbryta (voxelotor) — an oral, once-daily treatment — is marketed for the treatment of SCD. Novartis (NVS - Free Report) has Adakveo (crizanlizumab) in its portfolio to reduce the frequency of vaso-occlusive crises or pain crises in patients aged 16 years or above with SCD.
GlycoMimetics currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
GlycoMimetics, Inc. (GLYC) announced that the FDA has granted a Rare Pediatric Disease designation for its lead candidate rivipansel for the treatment of sickle cell disease (“SCD”) in patients 18 years old and younger. Sickle cell disease is a group of blood disorders typically inherited from a person's parents.
Shares of the company have decreased 38.2% year to date compared with the industry’s 7.6% decline.
Rivipansel is a glycomimetic drug candidate and the company plans to release full data set from the phase III RESET program at upcoming medical meetings.
The Rare Pediatric Disease designation makes the candidate eligible for a Rare Pediatric Disease Priority Review Voucher (“PRV”) upon approval. A PRV allows the holder of the voucher to receive an expedited six-month review from the FDA for new drug application or biologics license application instead of the usual ten-month review. Priority review vouchers are also awarded by the FDA for the development of treatments for certain tropical diseases and medical countermeasures.
There are some companies that are developing or have developed candidates for the treatment of SCD. bluebird (BLUE - Free Report) is developing lentiGlobin gene therapy for adult and adolescent patients with SCD. Global Blood Therapeutics’ Oxbryta (voxelotor) — an oral, once-daily treatment — is marketed for the treatment of SCD. Novartis (NVS - Free Report) has Adakveo (crizanlizumab) in its portfolio to reduce the frequency of vaso-occlusive crises or pain crises in patients aged 16 years or above with SCD.
GlycoMimetics currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on NVS - FREE
Get the latest research report on GLYC - FREE
Get the latest research report on BLUE - FREE